2020 National Adult and Influenza Immunization Summit Virtual Meeting

Influenza Prevention in the Era of COVID-19

May 21, 2020

Because the annual in-person National Adult and Influenza Immunization Summit meeting was cancelled in response to COVID-19 recommendations, a virtual Summit meeting was held on May 21, 2020. With its focus on influenza, the virtual meeting mirrored the typical final day of the in-person Summit. Please check below to view a recording of the entire virtual event, access individual presentations shared during the meeting, or review questions and answers provided by the presenters.

Influenza Prevention in the Era of COVID-19 Vaccine

 

SESSION ONE: Opening and CDC Influenza Updates

 

  • Opening Welcome
    L.J Tan, MS, PhD
    Chief Strategy Officer
    Immunization Action Coalition (IAC)
    Ilka Chavez, MPA
    Senior Public Health Advisor, Office of Infectious Disease and HIV/AIDS Policy
    Department of Health and Human Services (OIDP-HHS)
  • Setting the Stage (no slides)
    Nancy Messonnier, MD
    Director, National Center for Immunizations and Respiratory Diseases
    Centers for Disease Control and Prevention (CDC)
  • ACIP Influenza Update
    Lisa Grohskopf, MD, MPH
    Medical Officer, Influenza Division
    Centers for Disease Control and Prevention (CDC)

 

SESSION TWO: Partner Organization Updates

 

  • Adult IIS Project
    Rebecca Coyle, MSEd
    Executive Director
    American Immunization Registry Association (AIRA)
  • 2020–2021 AAFP Influenza Plan
    Amy Mullins, MD
    Medical Director, Quality and Science
    American Academy of Family Physicians (AAFP)
    Bellinda Schoof, MHA, CPHQ, CAE
    Director, Health of the Public and Science
    American Academy of Family Physicians (AAFP)
    Pamela Carter-Smith, MPA
    Clinical Policies Strategist, Health of the Public and Science
    American Academy of Family Physicians (AAFP)
  • Influenza Update
    Flor Munoz, MD, FAAP
    Associate Professor of Pediatrics,
    Infectious Diseases, Molecular Virology, and Microbiology
    Baylor College of Medicine,
    American Academy of Pediatrics (AAP)
  • ACP Update
    Selam Wubu, MPH
    Director, Center for Quality
    American College of Physicians (ACP)

 

SESSION THREE: Influenza Vaccine Manufacturer Updates

 

  • Closing Remarks (no slides)
    L.J Tan, M.S, PhD
    Chief Strategy Officer
    Immunization Action Coalition (IAC)

(to be posted soon)
Questions and Answers from the presenters

________________________________________________________________________

Developing COVID-19 Vaccines in Record Time: Platforms and Partnerships for Prevention

May 12, 2020

Global health leaders have all said that the long-term solution to ending the pandemic is the arrival of a vaccine or vaccines that can be rapidly deployed around the world. Yet the development of a vaccine is a complex undertaking, especially during a global pandemic of an unknown pathogen with uncertain epidemiology. Even so, many vaccine developers moved swiftly, using platform technologies to go from genetic sequence data to vaccine candidates in a few short weeks, shortening typical timelines by months and years.

During this virtual meeting, the panel members shown below discussed the path to clinical trials and shared their thoughts on how collaboration will bring life-saving vaccines to the world in this time of unprecedented need.

Please check below to view a recording of the entire panel discussion or to access individual presentations shared during the meeting.

Developing COVID-19 Vaccines in Record Time  

PANELISTS

 

  • Introduction
    Phyllis Arthur, MBA
    Vice President, Infectious Diseases & Diagnostics Policy
    BIO